PCRX - Pacira Sev?redent team up to expand access to pain drug Exparel for dental procedures
- Pacira BioSciences ( NASDAQ: PCRX ) is collaborating with Sev?redent Sourcing Solutions to provide expanded access to non-opioid pain drug Exparel for patients undergoing oral and maxillofacial procedures.
- The partnership with Sev?redent, a group purchasing organization, will provide access to Exparel (bupivacaine liposome injectable suspension) — including product training and onboarding support from Pacira — for more than 1.8K dental offices in the U.S., the company said in a Sept. 27 press release.
For further details see:
Pacira, Sev?redent team up to expand access to pain drug Exparel for dental procedures